Symbols / TAK
TAK Chart
About
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 57.09B |
| Enterprise Value | 4.80T | Income | 112.93B | Sales | 4.46T |
| Book/sh | 30.54 | Cash/sh | 414.62 | Dividend Yield | 3.66% |
| Payout | 279.05% | Employees | 47455 | IPO | — |
| P/E | 82.14 | Forward P/E | 34.09 | PEG | — |
| P/S | 0.01 | P/B | 0.59 | P/C | — |
| EV/EBITDA | 3.77 | EV/Sales | 1.07 | Quick Ratio | 0.54 |
| Current Ratio | 1.19 | Debt/Eq | 70.93 | LT Debt/Eq | — |
| EPS (ttm) | 0.22 | EPS next Y | 0.53 | EPS Growth | 3.30% |
| Revenue Growth | 4.20% | Earnings | 2026-05-13 | ROA | 2.47% |
| ROE | 1.50% | ROIC | — | Gross Margin | 65.53% |
| Oper. Margin | 10.85% | Profit Margin | 2.53% | Shs Outstand | 3.16B |
| Shs Float | 1.58B | Short Float | 0.21% | Short Ratio | 1.85 |
| Short Interest | — | 52W High | 18.82 | 52W Low | 12.99 |
| Beta | 0.10 | Avg Volume | 2.95M | Volume | 2.73M |
| Target Price | $19.66 | Recom | Strong_buy | Prev Close | $17.88 |
| Price | $18.07 | Change | 1.06% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$19.66
Mean price target
2. Current target
$18.07
Latest analyst target
3. DCF / Fair value
$3058.00
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$18.07
Low
$18.85
High
$20.77
Mean
$19.66
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2023-05-16 | main | TD Cowen | Outperform → Outperform | $20 |
| 2023-04-04 | main | TD Cowen | — → Outperform | $30 |
| 2023-03-16 | up | B of A Securities | Neutral → Buy | $20 |
| 2022-07-19 | up | Cowen & Co. | Market Perform → Outperform | $24 |
| 2021-10-07 | down | Morgan Stanley | Overweight → Equal-Weight | — |
| 2020-03-11 | main | JP Morgan | — → Overweight | $30 |
| 2019-11-01 | init | Cowen & Co. | — → Market Perform | $20 |
| 2019-09-24 | init | Jefferies | — → Buy | — |
News
RSS: Latest TAK news- Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? - Yahoo Finance Sat, 31 Jan 2026 08
- FDA Grants Priority Review for Takeda (TAK) and Protagonist’s Rusfertide in PV Treatment - Insider Monkey Sun, 08 Mar 2026 16
- ENTYVIO trial sees 47% of kids with moderate/severe colitis in remission - Stock Titan hu, 19 Feb 2026 08
- From the ground up: The faces behind APAC’s stock loan market - Securities Finance Times ue, 17 Feb 2026 08
- Technical Reactions to TAK Trends in Macro Strategies - Stock Traders Daily Mon, 16 Feb 2026 08
- Takeda Pharmaceutical’s Valuation After ENTYVIO Pediatric Data And TAK-861 Priority Review - simplywall.st ue, 24 Feb 2026 08
- Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? - Nasdaq Wed, 07 May 2025 07
- Takeda: Positives And Negatives Offset Each Other (NYSE:TAK) - Seeking Alpha Fri, 11 Jul 2025 07
- FDA grants priority review to new injection for blood disorder polycythemia vera - Stock Titan Mon, 02 Mar 2026 07
- Responsive Playbooks and the TAK Inflection - Stock Traders Daily hu, 20 Nov 2025 08
- Innovent Biologics, Takeda (NYSE: TAK) seal IO, ADC pact worth up to $11.4 billion - Stock Titan hu, 04 Dec 2025 08
- Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? - Yahoo Finance Fri, 04 Apr 2025 07
- Once-daily pill from Takeda helps many psoriasis patients reach clear skin - Stock Titan hu, 18 Dec 2025 08
- Takeda (NYSE: TAK) signs Innovent pact: $1.2B upfront; co-develop IBI363, license IBI343 - Stock Titan ue, 21 Oct 2025 07
- New Takeda pill targets root cause of rare sleep disorder - Stock Titan ue, 10 Feb 2026 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -63.21B | -41.62B | -15.96B | -27.07B |
| TaxRateForCalcs | 0.38 | 0.23 | 0.15 | 0.24 |
| NormalizedEBITDA | 1.24T | 1.08T | 1.26T | 1.12T |
| TotalUnusualItems | -165.32B | -179.38B | -103.12B | -113.11B |
| TotalUnusualItemsExcludingGoodwill | -165.32B | -179.38B | -103.12B | -113.11B |
| NetIncomeFromContinuingOperationNetMinorityInterest | 107.93B | 144.07B | 317.02B | 230.06B |
| ReconciledDepreciation | 761.40B | 728.00B | 664.40B | 583.15B |
| ReconciledCostOfRevenue | 1.46T | 1.35T | 1.12T | 996.61B |
| EBITDA | 1.07T | 900.33B | 1.16T | 1.01T |
| EBIT | 312.39B | 172.33B | 492.06B | 425.00B |
| NetInterestIncome | -141.67B | -140.46B | -123.39B | -123.48B |
| InterestExpense | 137.31B | 119.53B | 116.97B | 122.43B |
| InterestIncome | 19.64B | 11.29B | 5.51B | 4.59B |
| NormalizedIncome | 210.04B | 281.83B | 404.18B | 316.10B |
| NetIncomeFromContinuingAndDiscontinuedOperation | 107.93B | 144.07B | 317.02B | 230.06B |
| TotalExpenses | 4.10T | 3.90T | 3.44T | 3.02T |
| TotalOperatingIncomeAsReported | 342.59B | 214.07B | 490.50B | 460.84B |
| DilutedAverageShares | 3.21B | 3.16B | 3.14B | 3.15B |
| BasicAverageShares | 3.16B | 3.13B | 3.10B | 3.13B |
| DilutedEPS | 33.62 | 45.58 | 100.97 | 72.94 |
| BasicEPS | 34.18 | 46.05 | 102.14 | 73.57 |
| DilutedNIAvailtoComStockholders | 107.93B | 144.07B | 317.02B | 230.06B |
| NetIncomeCommonStockholders | 107.93B | 144.07B | 317.02B | 230.06B |
| NetIncome | 107.93B | 144.07B | 317.02B | 230.06B |
| MinorityInterests | -215.00M | -130.00M | -21.00M | -107.00M |
| NetIncomeIncludingNoncontrollingInterests | 108.14B | 144.20B | 317.04B | 230.17B |
| NetIncomeContinuousOperations | 108.14B | 144.20B | 317.04B | 230.17B |
| TaxProvision | 66.94B | -91.41B | 58.05B | 72.41B |
| PretaxIncome | 175.08B | 52.79B | 375.09B | 302.57B |
| OtherIncomeExpense | -169.31B | -172.91B | -89.34B | -120.00B |
| SpecialIncomeCharges | -172.92B | -170.25B | -109.56B | -88.90B |
| GainOnSaleOfPPE | 363.00M | 144.00M | 2.09B | 1.15B |
| GainOnSaleOfBusiness | 10.20B | 7.83B | 6.81B | 7.02B |
| OtherSpecialCharges | 37.57B | 63.37B | 24.61B | 3.70B |
| WriteOff | 18.38B | 12.74B | 30.63B | 20.72B |
| RestructuringAndMergernAcquisition | 127.53B | 102.11B | 63.23B | 72.64B |
| EarningsFromEquityInterest | -3.99B | 6.47B | 13.79B | -6.88B |
| GainOnSaleOfSecurity | 7.60B | -9.13B | 6.44B | -24.21B |
| NetNonOperatingInterestIncomeExpense | -141.67B | -140.46B | -123.39B | -123.48B |
| TotalOtherFinanceCost | 24.00B | 32.22B | 11.92B | 5.64B |
| InterestExpenseNonOperating | 137.31B | 119.53B | 116.97B | 122.43B |
| InterestIncomeNonOperating | 19.64B | 11.29B | 5.51B | 4.59B |
| OperatingIncome | 486.06B | 366.17B | 587.81B | 546.04B |
| OperatingExpense | 2.52T | 2.47T | 2.20T | 1.92T |
| OtherOperatingExpenses | 37.05B | 35.06B | 22.52B | 30.75B |
| DepreciationAmortizationDepletionIncomeStatement | 643.23B | 652.12B | 542.44B | 472.92B |
| DepreciationAndAmortizationInIncomeStatement | 643.23B | 652.12B | 542.44B | 472.92B |
| Amortization | 643.23B | 652.12B | 542.44B | 472.92B |
| AmortizationOfIntangiblesIncomeStatement | 643.23B | 652.12B | 542.44B | 472.92B |
| ResearchAndDevelopment | 730.23B | 729.92B | 633.33B | 526.09B |
| SellingGeneralAndAdministration | 1.10T | 1.05T | 997.31B | 886.36B |
| GrossProfit | 3.00T | 2.84T | 2.78T | 2.46T |
| CostOfRevenue | 1.58T | 1.43T | 1.24T | 1.11T |
| TotalRevenue | 4.58T | 4.26T | 4.03T | 3.57T |
| OperatingRevenue | 4.58T | 4.26T | 4.03T | 3.57T |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 17.30M | 13.41M | 27.77M | 22.65M |
| OrdinarySharesNumber | 1.57B | 1.57B | 1.55B | 1.56B |
| ShareIssued | 1.59B | 1.58B | 1.58B | 1.58B |
| NetDebt | 4.13T | 4.39T | 3.85T | 3.50T |
| TotalDebt | 4.52T | 4.84T | 4.38T | 4.35T |
| TangibleBookValue | -2.02T | -2.41T | -2.71T | -2.54T |
| InvestedCapital | 11.45T | 12.12T | 10.74T | 10.03T |
| WorkingCapital | 14.67B | 245.48B | -83.98B | 447.91B |
| NetTangibleAssets | -2.02T | -2.41T | -2.71T | -2.54T |
| CommonStockEquity | 6.94T | 7.27T | 6.35T | 5.68T |
| TotalCapitalization | 10.90T | 11.75T | 10.40T | 9.82T |
| TotalEquityGrossMinorityInterest | 6.94T | 7.27T | 6.35T | 5.68T |
| MinorityInterest | 895.00M | 741.00M | 549.00M | 504.00M |
| StockholdersEquity | 6.94T | 7.27T | 6.35T | 5.68T |
| OtherEquityInterest | 2.35T | 2.51T | 1.51T | 934.17B |
| TreasuryStock | 74.81B | 51.26B | 100.32B | 116.01B |
| RetainedEarnings | 1.19T | 1.39T | 1.54T | 1.48T |
| AdditionalPaidInCapital | 1.78T | 1.75T | 1.73T | 1.71T |
| CapitalStock | 1.69T | 1.68T | 1.68T | 1.68T |
| CommonStock | 1.69T | 1.68T | 1.68T | 1.68T |
| TotalLiabilitiesNetMinorityInterest | 7.31T | 7.83T | 7.60T | 7.49T |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 4.81T | 5.52T | 5.12T | 5.35T |
| OtherNonCurrentLiabilities | 633.44B | 768.77B | 599.66B | 536.16B |
| EmployeeBenefits | 135.43B | 143.88B | 127.59B | 145.85B |
| NonCurrentPensionAndOtherPostretirementBenefitPlans | 135.43B | 143.88B | 127.59B | 145.85B |
| TradeandOtherPayablesNonCurrent | 317.00M | 4.38B | 24.56B | 21.63B |
| NonCurrentDeferredLiabilities | 35.15B | 113.78B | 270.62B | 451.51B |
| NonCurrentDeferredTaxesLiabilities | 35.15B | 113.78B | 270.62B | 451.51B |
| LongTermDebtAndCapitalLeaseObligation | 3.97T | 4.48T | 4.04T | 4.14T |
| LongTermDebt | 3.97T | 4.48T | 4.04T | 4.14T |
| LongTermProvisions | 35.18B | 14.37B | 55.97B | 52.20B |
| CurrentLiabilities | 2.51T | 2.31T | 2.48T | 2.15T |
| OtherCurrentLiabilities | 815.40B | 764.00B | 752.37B | 781.02B |
| CurrentDebtAndCapitalLeaseObligation | 548.94B | 367.25B | 339.60B | 203.99B |
| CurrentDebt | 548.94B | 367.25B | 339.60B | 203.99B |
| OtherCurrentBorrowings | 548.94B | 367.25B | 339.60B | 203.99B |
| CurrentProvisions | 533.14B | 524.42B | 508.36B | 443.50B |
| PayablesAndAccruedExpenses | 609.04B | 657.43B | 881.61B | 717.22B |
| Payables | 609.04B | 657.43B | 881.61B | 717.22B |
| OtherPayable | 167.09B | 227.57B | 341.78B | 220.36B |
| TotalTaxPayable | 133.50B | 109.91B | 232.38B | 200.92B |
| IncomeTaxPayable | 133.50B | 109.91B | 232.38B | 200.92B |
| AccountsPayable | 308.45B | 319.95B | 307.45B | 295.93B |
| TotalAssets | 14.25T | 15.11T | 13.96T | 13.18T |
| TotalNonCurrentAssets | 11.73T | 12.55T | 11.56T | 10.58T |
| OtherNonCurrentAssets | 70.28B | 51.21B | 63.33B | 82.61B |
| NonCurrentDeferredAssets | 370.75B | 393.87B | 366.00B | 362.54B |
| NonCurrentDeferredTaxesAssets | 370.75B | 393.87B | 366.00B | 362.54B |
| InvestmentsAndAdvances | 361.93B | 430.61B | 378.86B | 330.13B |
| InvestmentinFinancialAssets | 351.12B | 340.78B | 279.68B | 233.55B |
| AvailableForSaleSecurities | 351.12B | 340.78B | 279.68B | 233.55B |
| LongTermEquityInvestment | 10.80B | 89.83B | 99.17B | 96.58B |
| GoodwillAndOtherIntangibleAssets | 8.96T | 9.68T | 9.06T | 8.23T |
| OtherIntangibleAssets | 3.63T | 4.27T | 4.27T | 3.82T |
| Goodwill | 5.32T | 5.41T | 4.79T | 4.41T |
| NetPPE | 1.97T | 1.99T | 1.69T | 1.58T |
| AccumulatedDepreciation | -1.31T | -1.22T | -1.01T | -870.21B |
| GrossPPE | 3.27T | 3.21T | 2.70T | 2.45T |
| ConstructionInProgress | 321.66B | 278.69B | 207.40B | 157.86B |
| MachineryFurnitureEquipment | 1.18T | 1.15T | 993.25B | 907.92B |
| BuildingsAndImprovements | 1.67T | 1.68T | 1.40T | 1.29T |
| LandAndImprovements | 104.34B | 105.84B | 98.23B | 98.65B |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.52T | 2.56T | 2.40T | 2.59T |
| OtherCurrentAssets | 159.60B | 168.88B | 160.87B | 141.10B |
| AssetsHeldForSaleCurrent | 13.40B | 9.34B | 15.23B | 0.00 |
| Inventory | 1.22T | 1.21T | 986.46B | 853.17B |
| OtherInventories | -1.00M | 1.00M | ||
| FinishedGoods | 323.51B | 349.59B | 269.04B | 224.10B |
| WorkInProcess | 552.20B | 522.67B | 436.51B | 404.09B |
| RawMaterials | 341.64B | 337.61B | 280.91B | 224.98B |
| Receivables | 725.25B | 697.61B | 681.69B | 724.38B |
| ReceivablesAdjustmentsAllowances | -119.48B | -106.24B | -99.26B | -92.79B |
| OtherReceivables | 58.05B | 55.96B | 74.00B | 79.13B |
| TaxesReceivable | 15.79B | 29.21B | 32.26B | 27.73B |
| AccountsReceivable | 770.90B | 718.67B | 674.69B | 710.30B |
| CashCashEquivalentsAndShortTermInvestments | 405.59B | 472.89B | 553.70B | 875.00B |
| OtherShortTermInvestments | 20.48B | 15.09B | 20.17B | 25.30B |
| CashAndCashEquivalents | 385.11B | 457.80B | 533.53B | 849.70B |
| CashEquivalents | 151.37B | 252.61B | 303.97B | 460.64B |
| CashFinancial | 233.74B | 205.19B | 229.56B | 389.06B |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| FreeCashFlow | 677.56B | 235.61B | 343.47B | 937.07B |
| RepurchaseOfCapitalStock | -51.86B | -2.33B | -26.93B | -77.53B |
| RepaymentOfDebt | -1.37T | -375.49B | -400.07B | -849.81B |
| IssuanceOfDebt | 1.05T | 377.00B | 115.00B | 249.33B |
| CapitalExpenditure | -379.62B | -480.73B | -633.69B | -186.04B |
| EndCashPosition | 385.11B | 457.80B | 533.53B | 849.70B |
| BeginningCashPosition | 457.80B | 533.53B | 849.70B | 966.22B |
| EffectOfExchangeRateChanges | -11.38B | 26.20B | 22.93B | 28.76B |
| ChangesInCash | -61.30B | -101.93B | -339.09B | -145.28B |
| FinancingCashFlow | -751.42B | -354.42B | -709.15B | -1.07T |
| CashFlowFromContinuingFinancingActivities | -751.42B | -354.42B | -709.15B | -1.07T |
| NetOtherFinancingCharges | 30.23B | 33.96B | -9.18B | -385.00M |
| InterestPaidCFF | -112.98B | -100.38B | -108.56B | -108.21B |
| CashDividendsPaid | -302.50B | -287.19B | -279.42B | -283.67B |
| CommonStockDividendPaid | -279.42B | -283.67B | -283.36B | |
| NetCommonStockIssuance | -51.86B | -2.33B | -26.93B | -77.53B |
| CommonStockPayments | -51.86B | -2.33B | -26.93B | -77.53B |
| NetIssuancePaymentsOfDebt | -314.31B | 1.51B | -285.07B | -600.48B |
| NetShortTermDebtIssuance | 27.49B | 277.00B | 40.00B | -2.00M |
| ShortTermDebtPayments | -2.00M | -149.04B | ||
| ShortTermDebtIssuance | 27.49B | 277.00B | 40.00B | |
| NetLongTermDebtIssuance | -341.80B | -275.49B | -325.07B | -600.48B |
| LongTermDebtPayments | -1.37T | -375.49B | -400.07B | -849.81B |
| LongTermDebtIssuance | 1.02T | 100.00B | 75.00B | 249.33B |
| InvestingCashFlow | -367.06B | -463.86B | -607.10B | -198.12B |
| CashFlowFromContinuingInvestingActivities | -367.06B | -463.86B | -607.10B | -198.13B |
| NetOtherInvestingChanges | -1.11B | -4.00B | -3.05B | -7.33B |
| InterestReceivedCFI | 17.66B | 11.16B | 5.05B | 2.92B |
| DividendsReceivedCFI | 635.00M | 13.19B | 3.56B | 3.40B |
| NetInvestmentPurchaseAndSale | -81.94B | -32.05B | 12.10B | 8.58B |
| SaleOfInvestment | 29.44B | 8.02B | 22.25B | 16.92B |
| PurchaseOfInvestment | -111.38B | -40.07B | -10.15B | -8.34B |
| NetBusinessPurchaseAndSale | 77.24B | 19.96B | 7.96B | -21.48B |
| SaleOfBusiness | 78.25B | 19.96B | 7.96B | 28.20B |
| PurchaseOfBusiness | -1.00B | 0.00 | 0.00 | -49.67B |
| NetIntangiblesPurchaseAndSale | -178.83B | -305.31B | -493.03B | -62.78B |
| PurchaseOfIntangibles | -178.83B | -305.31B | -493.03B | -62.78B |
| NetPPEPurchaseAndSale | -200.72B | -166.81B | -139.69B | -121.44B |
| SaleOfPPE | 78.00M | 8.61B | 962.00M | 1.81B |
| PurchaseOfPPE | -200.79B | -175.42B | -140.66B | -123.25B |
| OperatingCashFlow | 1.06T | 716.34B | 977.16B | 1.12T |
| CashFlowFromContinuingOperatingActivities | 1.06T | 716.34B | 977.16B | 1.12T |
| TaxesRefundPaid | -150.41B | -202.04B | -185.97B | -140.42B |
| ChangeInWorkingCapital | -59.37B | -256.00B | -25.26B | 98.61B |
| ChangeInOtherWorkingCapital | 45.17B | -126.90B | 31.90B | -58.09B |
| ChangeInOtherCurrentLiabilities | -3.49B | -18.57B | 31.67B | -49.61B |
| ChangeInPayablesAndAccruedExpense | -7.12B | -9.89B | -84.80B | 125.16B |
| ChangeInPayable | -7.12B | -9.89B | -84.80B | 125.16B |
| ChangeInInventory | -34.97B | -115.74B | -79.16B | -46.15B |
| ChangeInReceivables | -58.96B | 15.10B | 75.13B | 127.29B |
| OtherNonCashItems | 153.41B | 160.20B | 18.01B | 184.31B |
| StockBasedCompensation | 72.87B | 70.87B | 60.67B | 43.37B |
| UnrealizedGainLossOnInvestmentSecurities | -602.00M | 20.76B | 3.99B | -11.20B |
| AssetImpairmentCharge | 106.53B | 150.02B | 64.39B | 54.52B |
| DeferredTax | 66.94B | -91.41B | 58.05B | 72.41B |
| DeferredIncomeTax | 66.94B | -91.41B | 58.05B | 72.41B |
| DepreciationAmortizationDepletion | 761.40B | 728.00B | 664.40B | 583.15B |
| DepreciationAndAmortization | 761.40B | 728.00B | 664.40B | 583.15B |
| OperatingGainsLosses | -1.72B | -8.25B | 1.83B | 8.19B |
| EarningsLossesFromEquityInvestments | 3.99B | -6.47B | 8.63B | 15.37B |
| GainLossOnSaleOfPPE | 4.50B | 6.05B | 10.00M | 655.00M |
| GainLossOnSaleOfBusiness | -10.20B | -7.83B | -6.81B | -7.83B |
| NetIncomeFromContinuingOperations | 108.14B | 144.20B | 317.04B | 230.17B |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TAK
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|